Study of liver fibrosis diagnosis, comparison of ELF score and/or collagen neo-epitope with various liver fibrosis markers, ultrasound-based elastography, and magnetic resonance elastography.

Study of liver fibrosis diagnosis, comparison of ELF score and/or collagen neo-epitope with various liver fibrosis markers, ultrasound-based elastography, and magnetic resonance elastography. - Study of liver fibrosis diagnosis, comparison of ELF score and/or collagen neo-epitope with various liver fibrosis markers, ultrasound-based elastography, and magnetic resonance elastography.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036142

Enrollment

740

Registered

2019-03-09

Start date

2019-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with chronic liver diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with diagnosed chronic liver disease (chronic hepatitis B, chronic hepatitis C, nonalcoholic fatty liver disease, alcoholic liver disease, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis) by interview, blood collection, imaging studies. 2. Patients who are provided a written informed consent.

Exclusion criteria

Exclusion criteria: Patients judged inappropriate by doctor

Design outcomes

Primary

Measure	Time frame
Comparison of ELF score and/or collagen neo-epitope with liver stiffness measured by magnetic resonance elastography and/or ultrasound-based elastography	—

Secondary

Measure	Time frame
1. Comparison of ELF score and collagen-neo epitope with various liver fibrosis markers (type IV collagen 7S, M2BPGi, autotaxin, hyaluronic acid) and various scoring systems (Fib-4, NAFLD fibrosis score) 2. Analysis of factors related to ELF scores 3. Comparison of ELF score and/or collagen neo-epitope with liver fibrosis stage diagnosed by liver biopsy 4. Utility as liver fibrosis biomarker by follow-up of ELF score and/or collagen neo-epitope over time	—

Measure

Time frame

1. Comparison of ELF score and collagen-neo epitope with various liver fibrosis markers (type IV collagen 7S, M2BPGi, autotaxin, hyaluronic acid) and various scoring systems (Fib-4, NAFLD fibrosis score) 2. Analysis of factors related to ELF scores 3. Comparison of ELF score and/or collagen neo-epitope with liver fibrosis stage diagnosed by liver biopsy 4. Utility as liver fibrosis biomarker by follow-up of ELF score and/or collagen neo-epitope over time

—

Countries

Japan

Contacts

Public ContactTakashi Kobayashi

Yokohama City University Graduate School of Medicine Department of Gastroenterology and Hepatology

takobayashi-hok@umin.ac.jp0457872640

Outcome results